v 8

αVβ8-IN-1是一种αVβ8 integrin抑制剂,抑制多种肿瘤细胞（EMT6、CT26、KPC、TKCC-10）的生长，可用于研究肿瘤、特发性肺纤维化 (IPF)、非特异性间质性肺炎 (NSIP) 等等。

Amyloid-β (1-8, A2V) is a truncated form of amyloid-β (Aβ) that contains a valine to alanine substitution at position 2 of the Aβ numbering convention (Aβ A2V), which corresponds to position 673 of the amyloid precursor protein (APP) numbering convention (APP A673V). An Aβ (1-40) (Aβ40) A2V peptide increases the production of Aβ and the rate and amount of amyloid fibril formation in vitro, effects that can be reduced by coincubation with wild-type Aβ40. Aβ40 and Aβ42 levels are increased in CHO cells expressing the Aβ A2V mutation and in fibroblasts derived from patients with the Aβ A2V mutation. As a homozygous mutation, Aβ A2V is correlated with Alzheimer's disease with distinctive pathological features, but disease does not develop in patients with a heterozygous Aβ A2V mutation.

Anti-Mouse Vβ8 TCR Antibody (F23.1) 是一种源自小鼠的 IgG2a, κ 类别抗体，专门用于抑制小鼠的 Vβ8 TCR。

β-Amyloid (1-8, A2V) 是β-Amyloid (1-8)的变异体。

Jmv 81 is a bioactive chemical.

Poly(acrylic acid) (Mv 8000000) 一种在生化反应中使用的试剂。

AS-601811 是类固醇 5α还原酶抑制剂和雄激素受体调节剂，可用于研究脱发和痤疮。

Tetrahydrocurcumin (HZIV 81-2) 是从姜黄中发现的一种天然产物，是姜黄素的主要代谢产物，可抑制 CYP2C9和 CYP3A4，具有很强的抗氧化和心脏保护作用。

Tetrahydrocurcumin D6 is a deuterium labeled Tetrahydrocurcumin. Tetrahydrocurcumin displays inhibitory activity for CYP2C9 and CYP3A4.

RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively).

Tafluprost acid is a selective agonist at the prostaglandin F receptor.

JV8 是一种BRD4 PROTAC降解剂，能够促进BRD4的泛素化和降解，并诱导细胞凋亡 (Apoptosis)。在小鼠4T1原位肿瘤模型中，JV8 展现出抗肿瘤活性。

JTV-803 is a factor Xa inhibitor. JTV-803 showed a competitive inhibitory effect on human factor Xa, with a K(i) value of 0.019 microM and IC(50) value of 0.081 microM. JTV-803 was 100 times more selective in inhibiting human factor Xa as compared to its

Benfosformin is a bioactive chemical.

Fostroxacitabine bralpamide (MIV-818) is an orally active Troxacitabine-based nucleotide prodrug. Fostroxacitabine bralpamide has anticancer effects.

RET-IN-4 is a highly effective and specific RET inhibitor that can be administered orally. It demonstrates remarkable potency, with IC50 values of 1.29 nM, 1.97 nM, and 0.99 nM for inhibiting RET variants including RET (WT), RET (V804M), and RET (M918T), respectively. Moreover, RET-IN-4 exhibits superior selectivity towards kinases JAK2 (IC50 of 4.4 nM) and FLT3 (IC50 of 30.8 nM). Additionally, RET-IN-4 possesses pronounced anticancer properties.

AD80 是多激酶抑制剂，可抑制 RET、RAF、SRC 和 S6K，并大大降低 mTOR 活性。

ARV-825 是一种双功能 PROTAC，蛋白水解靶向嵌合体，将 BRD4 募集到 E3 泛素连接酶大脑中，导致 BRD4 在所有测试的 BL 细胞系中快速、有效和延长降解。对 BRD4 的 BD1 和 BD2 结构域具有高亲和力，Kd 值分别为 90 和 28 nM。

CPI-444 (V81444) 是一种选择性的，可口服的 A2A 受体 (A2AR) 拮抗剂，可诱导抗肿瘤反应。

Tilavonemab (ABBV-8E12) 是一种与人微管相关蛋白 tau 的 N 端结合的单克隆抗体，通过结合 tau 蛋白的 N 端氨基酸残基来靶向 tau 蛋白。Tilavonemab 阻断人和小鼠神经元摄取 tau 聚集体的能力，可用于研究神经系统疾病。

RET-IN-23 是一种可口服且具有高效性的 RET 抑制剂，具有显著的抗肿瘤活性，可用于研究非小细胞肺癌。

Selpercatinib (LOXO-292) 是 RET 激酶抑制剂，抑制 RET (WT)、RET (V804M) 、RET (G810R)的 IC50分别为 14.0 nM、24.1 nM、530.7 nM，具有抗肿瘤活性。

RET V804M-IN-1 (RETV804M kinase inhibitor) 是一种 wt-RET 选择性的RETV804M 激酶抑制剂，其IC50=20 nM。

NVP-DFV890 是 一种靶向 NLRP3 的抑制剂，可用于免疫疾病相关研究。